Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Notizie Vai al feed delle notizie
Biolargo reports 66% revenue decline to $1.1 million in the quarter
Biolargo released results for the quarter ended March 31, 2026, recording a 66.06% decline in revenue compared with the same period last year. Revenue fell from $3.3 million to $1.1 million. » Altro su finanzen.net
BioLargo reports mixed Q4 2025 results: revenue decline, doubled services business
BioLargo reported total revenue of $7.8 million for 2025 and a net loss of $15.2 million. The services business doubled to $2.0 million, cash stood at $3.9 million, and the termination of the Pooph license led to significant revenue losses. The stock fell 5.32% pre-market and was trading near its 52-week low; management plans to focus on commercialization in Clyra Medical and AEC Water Treatment in 2026. EPS estimates for 2026 are -$0.01. » Altro su de.investing.com
BioLargo reports Q3 revenue halved and burdensome loan loss from legal dispute
BioLargo recorded a roughly 50% year-on-year revenue decline in the third quarter of 2025 and missed earnings expectations. A loan loss of $3.85 million from the legal dispute with Poof weighed on results; EPS remained negative and revenue was below forecasts. The stock fell 7.87% to $0.1699 and is trading near its 52-week low. The company holds $4.5 million in cash and continues to focus on PFAS remediation, sodium-based battery technology and the rollout of Clyra‑Medical to drive growth. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 1,09 Mln | 53,59% |
| Utile lordo | 591,44K | 50,94% |
| Utile netto | -2,42 Mln | 139,73% |
| EBITDA | -3,17 Mln | 116,93% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 27,7 Mln € |
Numero di azioni | 320,88 Mln |
Massimo/minimo a 52 settimane | 0,20 € - 0,069 € |
| Dividendi | No |
Beta | -0,12 |
Rapporto P/E | -2,21 |
Rapporto PEG | 0,02 |
Rapporto P/B | -17,33 |
Rapporto P/S | 7,86 |
Profilo aziendale
BioLargo, Inc. erfindet, entwickelt und vermarktet verschiedene Plattformtechnologien. Die Technologien des Unternehmens lösen schwierige Umweltprobleme wie die Verunreinigung durch Per- und Polyfluoralkylsubstanzen, fortschrittliche Wasser- und Abwasseraufbereitung, industrielle Geruchs- und VOC-Kontrolle, Luftqualitätskontrolle und Infektionskontrolle. Das Unternehmen verfügt über verschiedene erteilte Patente, hat eine Reihe von Produkten in der Pipeline und bietet einen umfassenden Service im Bereich Umwelttechnik. Zu den Produkten des Unternehmens gehören das Advanced Oxidation System, ein Wasseraufbereitungsgerät, das eine Reihe von oxidativen und energetischen Jod- und anderen Molekülarten erzeugt; der Aqueous Electrostatic Concentrator, ein Wasseraufbereitungssystem, das Per- und Polyfluoralkyl-Substanzen aus dem Wasser entfernt; CupriDyne Clean-Industrieprodukte, die schwierige Gerüche und flüchtige organische Verbindungen in verschiedenen industriellen Umgebungen reduzieren und beseitigen; und fortschrittliche Wundpflegeprodukte. BioLargo, Inc. wurde 1991 gegründet und hat seinen Sitz in Westminster, Kalifornien.
| Nome | BIOLARGO INC. |
| CEO | Dennis Calvert |
| Sede centrale | Westminster,
ca Stati Uniti |
| Sito web | |
| Settore | Industria |
| Industria | Prodotti per l'edilizia |
| Quotazione in borsa | 22/03/2007 |
| Dipendenti | 45 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Pnk | BLGO |
Scopri gli asset
Gli azionisti di BIOLARGO INC. investono anche nei seguenti asset
